<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Samuel Gershon’s comments on Ronald Pies’ “Do antipsychotics thin the brain?”  Journal of Clinical Psychopharmacology 2018; 38 (3): 167- 9.</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Samuel Gershon’s comments on Ronald Pies’ “Do antipsychotics thin the brain?”  Journal of Clinical Psychopharmacology 2018; 38 (3): 167- 9." />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2018-10-19T22:23:24+00:00" />
<meta name="DC.date" content="2018-10-19T22:23:24+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEX677F.HTM?id=642" />
<link rel="next" href="INDEX4095.HTM?id=3972" />
<link rel="prev" href="INDEXEEC3.HTM?id=2410" />
<link rel="canonical" href="INDEX1263.HTM?id=2712" />



</head>
<body id="pageUID-2712">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li id="current"><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEX677F.HTM?id=642" target="_self">Perspectives</a>&nbsp;/&nbsp;Samuel Gershon’s comments on Ronald Pies’ “Do antipsychotics thin the brain?”  Journal of Clinical Psychopharmacology 2018; 38 (3): 167- 9.</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Perspectives</li><li><a href="INDEX716E.HTM?id=3214" target="_self">Thomas A. Ban: A brief historical exchange between Larry Stein and Joseph Knoll</a><span class="hidden">.</span></li><li><a href="INDEXA0A5.HTM?id=1439" target="_self">Thomas A. Ban: In historical perspective. Peralta, Cuesta and their Associates findings on the highest familiality of Leonhard’s classification in polynosologic study</a><span class="hidden">.</span></li><li><a href="INDEX1E45.HTM?id=3093" target="_self">Thomas A. Ban: The Ewen Cameron Story.</a><span class="hidden">.</span></li><li><a href="INDEX2D56.HTM?id=899" target="_self">Thomas A. Ban: The RDoC in historical perspective</a><span class="hidden">.</span></li><li><a href="INDEXA59C.HTM?id=2465" target="_self">Barry Blackwell’s comment on  de Leon J, Wise TN, Balon R, Fava G: Dealing with Difficult Medical Colleagues published in Psychotherapy and Psychosomatics</a></li><li><a href="INDEX006F.HTM?id=1046" target="_self">Barry Blackwell: Risk and relevance to lithium usage</a><span class="hidden">.</span></li><li><a href="INDEX4ECD.HTM?id=2171" target="_self">Barry Blackwell’s comment (Harvey V. Fineberg: Conflict of Interest: Why Does It Matter? Viewpoint. JAMA 2017; 317: 8)</a></li><li><a href="INDEXEEC3.HTM?id=2410" target="_self">W. Edwin Fann A History of The Tennessee Neuropsychiatric Institute</a><span class="hidden">.</span></li><li><strong>Samuel Gershon’s comments on Ronald Pies’ “Do antipsychotics thin the brain?”  Journal of Clinical Psychopharmacology 2018; 38 (3): 167- 9.</strong></li><li><a href="INDEX4095.HTM?id=3972" target="_self">Samuel Gershon’s comment on Plinio C. Casarotto et al.’s Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.</a><span class="hidden">.</span></li><li><a href="INDEXD9DB.HTM?id=4095" target="_self">Samuel Gershon’s comment on Herwig Czech, Gabor S. Ungvari, Kamila Uzarczyk, Paul Wydlow and Gabor Gazdag’s paper on ECT in the shadow of the gas chamber and Gabor Gazdag, Gabor S. Ungvari and Herwig Czech’s paper on Mass killing under the guise of ECT.</a></li><li><a href="INDEX91E8.HTM?id=3234" target="_self">Laszlo Gyermek: The role of the tropane skeleton in drug research</a></li><li><a href="INDEX9CCB.HTM?id=3980" target="_self">Carlos Hojaij’s Comment on Carlos Morra’s “The Mental Status Examination and General Psychopathology, Volume 1, Sensory-perception.”</a></li><li><a href="INDEXA65E.HTM?id=1842" target="_self">Carlos R. Hojaij: Ethics for psychiatrists</a><span class="hidden">.</span></li><li><a href="INDEXB382.HTM?id=3156" target="_self">Gerd Huber and Gisela Gross:  The Development of the Psychopathology in Germany in the Last Decades [20th century] with an Introduction by Carlos R. Hojaij</a><span class="hidden">.</span></li><li><a href="INDEX6872.HTM?id=1653" target="_self">Martin M. Katz’s comment on Jose de Leon’s article “Focusing on drug versus disease mechanisms and on clinical subtyping to advance personalized medicine”</a></li><li><a href="INDEXF441.HTM?id=2627" target="_self">Carl Lange: On periodical depressions and their pathogenesis  Speech delivered to the ‘Medical Society of Copenhagen', 19 January 1886</a><span class="hidden">.</span></li><li><a href="INDEX0BC7.HTM?id=3235" target="_self">Alex Last: BBC Witness History. The First Antipsychotic Drug. An interview of Thomas Ban.</a><span class="hidden">.</span></li><li><a href="INDEXD786.HTM?id=3226" target="_self">Carlos Morra: Argentina’s controversial National Law of Mental Health No. 26, 657.</a><span class="hidden">.</span></li><li><a href="INDEX36B3.HTM?id=3981" target="_self">Carlos Morra: The use of human-induced pluripotent stem cells (iPSC) in schizophrenia. Will this technology generate a leap forward in the disease´s modeling?</a></li><li><a href="INDEX314C.HTM?id=4116" target="_self">Review of the modern gene editing techniques: CRISPR-Cas applications in iPSC-derived cultures (Carlos Morra: Biomarkers to replace clinical endpoints for the generation of diagnostic hypotheses with the potential to guide the development of novel psychot</a></li><li><a href="INDEX8FB9.HTM?id=3836" target="_self">János Radó’s comment on  Lin, Zhang, Feng, et al., “Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus.”</a><span class="hidden">.</span></li><li><a href="INDEXBE5E.HTM?id=3049" target="_self">Janos Radó:  Mechanism of Lithium Induced Polyuria in Historical Perspective</a><span class="hidden">.</span></li><li><a href="INDEX74F9.HTM?id=3247" target="_self">Janusz Rybakowski: Emil Kraepelin's dichotomy of “endogenous psychoses” in historical perspective</a><span class="hidden">.</span></li><li><a href="INDEX9150.HTM?id=3730" target="_self">Mary Seeman’s comment on Jack R. Foucher et al.’s paper on Wernicke-Kleist-Leonhard phenotypes of endogenous psychoses: A review of their validity.</a></li><li><a href="INDEX23E4.HTM?id=3722" target="_self">Philip Seeman and Mary V. Seeman: The Dopamine Hypothesis of Schizophrenia in Historical Perspective.</a><span class="hidden">.</span></li><li><a href="INDEXB8A6.HTM?id=3964" target="_self">Edward Shorter’s comment on Herwig Czech, Gabor Ungvari, Kamila Uzarzzyk and Gabor Gazdag’s 2020 paper, “Electroconvulsive therapy in the  shadow of the gas chamber. Medical innovations and human experimentation in Auschwitz.”</a></li><li><a href="INDEXFC4E.HTM?id=3462" target="_self">Edward Shorter’s comment on Jack R. Foucher et al.’s paper on  Wernicke-Kleist-Leonhard phenotypes of endogenous psychoses: A review of their validity</a><span class="hidden">.</span></li><li><a href="INDEXE275.HTM?id=3965" target="_self">Hector Warnes’ comment on Despoina Asanaglou et al.’s 2021 paper, “Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors.”</a></li><li><a href="INDEX4562.HTM?id=3837" target="_self">Hector Warnes’ comment  on  Silberman, Balon, Starcevic et al “Benzodiazepines: it ́s time to return to the evidence.”</a></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><div id="c4544" class="csc-default"><h1>Samuel Gershon’s comments on Ronald Pies’ “Do antipsychotics thin the brain?”<br />Journal of Clinical Psychopharmacology 2018; 38 (3): 167- 9.</h1>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is a thoughtful and carefully presented paper and, in my view,poses a question that has been asked many times and put aside. In the 1970-80s Earl Usdin,one of the administrators at the USNational Institute of Mental Health (NIMH),funded some studies in primatesfocussing on this question.He died (1984) during this project and I do not remember seeing any publicationsabout his work.<a name="_GoBack"></a>I thought that so many years after the introduction of these drugs in massive amounts we should have more information about this phenomenon.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This question has been present as a shadow for the past 70 years.It has come back to haunt us many times with the appearance of pathological neurological effects, such as Parkinson’s Syndrome, which we went ahead and medicated with antiparkinsonianmedication, but often continued with the offending antipsychotic agent. I am sure some clinicians did scratch their head and question, subtly, is this going to be OK? We also saw acute dystonic reactions, akathisia, brain malignant syndrome&nbsp;and the drastic tardive dyskinesia. So, we were all aware that the brain was having a bad time every now and again.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; I myself had these thoughts repeatedly and kept on asking people about this as possible hidden damage to the brain and its functions. Most people shook it off and felt symptoms were being treated by these anticholinergic drugs. </p>
<p>So, now we have some additional urgency becausemany people are proposing early treatment intervention for children and adolescents with the real concern being,for example, can you make a reliable diagnosis of, say Bipolar Disorder, in young children and adolescents and then expose them to compounds like these over which still hangs this unresolved question of “thin brain”?</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These questions bring us back again and again to diagnostic questions about some of our psychiatric disorders. Manic depressive disorder as a diagnostic issue can be difficult and complex in the adult, but in a developing teenager or adolescent the alterations over time in this age group can present a changing picture and thus the introduction of medication at one phase may have to be revised and with it the “medication plan” whichoffers the introduction of several different medications to this still developing individual. </p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Another diagnostic label that can cause questions is schizoaffective disorder;the label almost invites the presentation of multiple medications at the outset. The practicalities of clinical care raise another common practice that is: if treatment A is either not effective or only minimally so and then often drug B is added to A this practice of poly pharmacy&nbsp;becomes more common in busy out-patient care. Thus, multiple drug exposures are more common and obviously the possibility of increased neurotoxicity.</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; It appears that the question posed by Pies’ report really forces us to go back to base to address some of the fundamental issues left behind on the aggressive needs of clinical practice.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; I am the fortunate recipient of Psychiatric Times and in this year’s May Supplementthere are several papers relevant to this issue:</p>
<p>&nbsp;</p>
<p>1. “Subthreshold bipolarity, low-dose lithium and non-drug options for complex depressions”by James Phelps &nbsp; </p>
<p>2.“Not bipolar, but not unipolar either”; and </p>
<p>3. “Diagnosis - or lithium anyway” </p>
<p>&nbsp;</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; I believe Barry Blackwell would be able to describe this sort of thinking and practice. It is a reflection of the unused ability of our current diagnostic labels, as in DSM 5 of the American Psychiatric Association,and the random use of medications to fit this unfit table animal. In my view, these practices all need be considered as an urgent need for answering the questions raised by the “Thin Brain”paper.</p>
<p>&nbsp;</p>
<p>October 25, 2018</p></div><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>